Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering
Research Triangle Park, N.C. – October 8, 2019 – Metabolon, Inc., the global leader in revealing biological insights through metabolomics, announces the appointment of Karl Bradshaw, Ph.D., as Vice President of Biopharma Strategy and Partnering.
“We welcome Karl at an exciting time when Metabolon is implementing new strategies to increase our growth and prominence as the biotech partner capable of addressing the most difficult questions in the life sciences through our unmatched approach to metabolomics,” said Rohan Hastie, Ph.D., President and CEO, Metabolon. “Karl brings a wealth of experience in corporate strategy and development vital for this stage of our growth.”
Dr. Bradshaw will be responsible for delivering biopharma partnerships that leverage Metabolon’s unique technical capabilities and biological insights to generate significant mutual value for both parties.
“It is apparent to me that Metabolon is a clear world leader in metabolomics and is an essential component of the multi-omics revolution,” said Dr. Bradshaw. “I am thrilled to help lead the company’s journey to accelerate research and product development success across the biopharma industry by revealing previously unseen biological insights.”
Dr. Bradshaw joins Metabolon from AstraZeneca, where he most recently served as Senior Director of Corporate Strategy and Development helping to advance business strategy through execution of mergers and acquisitions, divestitures and investments that bolstered core growth platforms and therapy areas. Dr. Bradshaw held several roles during his six-year tenure at AstraZeneca, including Head of Competitive Intelligence for infection, neuroscience and GI, and Business Development Director for AstraZeneca’s Antibiotics Business Unit. Prior to joining AstraZeneca, Dr. Bradshaw worked for seven years as Vice President of equity research at Morgan Stanley, where he gained extensive experience in financial analysis, modelling and valuation of biotech and medtech companies, as well as an excellent understanding of global healthcare sector trends and underlying market demographics.
Dr. Bradshaw earned his undergraduate degree in biological sciences from Birmingham University and a doctorate in neuroscience from University College London. He conducted postdoctoral work at the National Institute for Medical Research, later completing an MPhil in Bioscience Enterprise from Cambridge University.